- Home
- SGMT
as 05-30-2025 2:41pm EST
Stocks
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 71.2M | IPO Year: | 2023 |
| Target Price: | $25.67 | AVG Volume (30 days): | 390.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.73 - $7.38 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -98.27% |
Latest Sagimet Biosciences Inc. Series A News
SGMT Breaking Stock News: Dive into SGMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
GlobeNewswire
22 days ago
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Simply Wall St.
a month ago
Top Penny Stocks To Watch In April 2025
GlobeNewswire
a month ago
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
GlobeNewswire
3 months ago
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
MT Newswires
3 months ago
Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials
GlobeNewswire
3 months ago
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
Insider Monkey
3 months ago
Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?
Compare SGMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMT Sagimet Biosciences Inc. Series A - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.